Mineralys Therapeutics (MLYS) Total Liabilities (2022 - 2026)

Mineralys Therapeutics has disclosed Total Liabilities across 5 years of filings, most recently posting $14.7 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $14.7 million, up 9.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.7 million (up 9.95% YoY), and the FY2025 annual result was $15.1 million, up 3.19% from the prior year.
• Total Liabilities came in at $14.7 million for Q1 2026 at Mineralys Therapeutics, down from $15.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $166.7 million in Q4 2022 to a low of $6.2 million in Q2 2023.
• The 5-year median for Total Liabilities is $19.2 million (2024), against an average of $29.5 million.
• Across the five-year window, Total Liabilities slumped 93.71% in 2023 and surged 357.5% in 2024, its largest moves.
• Mineralys Therapeutics' Total Liabilities stood at $166.7 million in 2022, then sank by 93.71% to $10.5 million in 2023, then soared by 39.73% to $14.6 million in 2024, then gained by 3.19% to $15.1 million in 2025, then retreated by 2.61% to $14.7 million in 2026.
• The last three Total Liabilities figures came in at $14.7 million (Q1 2026), $15.1 million (Q4 2025), and $23.5 million (Q3 2025), per Business Quant data.